Home » BIOVAIL SHAREHOLDERS SLAP SAC, OTHERS WITH $4B SUIT
BIOVAIL SHAREHOLDERS SLAP SAC, OTHERS WITH $4B SUIT
About a month after
Biovail Corp. filed a $6 billion action against 22 defendants, including hedge
fund SAC Capital Management, its founder, Steven Cohen, and the research firm
now known as Gradient Analytics, shareholders of the Canadian pharmaceutical have
followed suit with their own $4 billion class action against basically the same
group.
Institutional
Investor
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May